Partner Notification for Chlamydia in Primary Care

Status Completed

Clinical Trial Summary

The purpose of this study was to compare the effectiveness of partner notification by general practice nurses with referral to a specialist clinic for people with genital chlamydia diagnosed in a community setting. We hypothesised that referral to a specialist would be more effective in ensuring treatment of the sexual partners of infected people than the simpler nurse-led strategy.

Clinical Trial Description

Partner notification (contact tracing) is essential to the control of sexually transmitted infections. Reports of new chlamydia infections have increased by 66% in the past five years. A National Chlamydia Screening Programme in England, and increasing primary care provision of sexual health care are part of the United Kingdom Government's strategy for tackling increasing rates of sexually transmitted infections. New strategies for managing chlamydia in non-specialist settings are urgently required: genitourinary medicine clinics are failing to cope with their increasing workload; and 45% of cases detected in the chlamydia screening pilot studies were diagnosed in general practice.

Partner notification involves informing the sexual partners of someone with a sexually transmitted infection of the possibility of exposure, offering them diagnosis and treatment, and providing advice about preventing future infection. In the United Kingdom, this is usually done by specialist sexual health advisers in departments of genitourinary medicine. The effectiveness of partner notification in non-specialist settings in developed countries is not known. We conducted a randomised controlled trial to compare the effectiveness of practice nurse-led partner notification with referral to a genitourinary clinic for partner notification conducted by a specialist health adviser, and to compare the resources used by each strategy.

Comparisons: Partner notification at the time of receiving diagnosis and treatment by general practice nurses who received a one-day training course and ongoing support by telephone calls or visits from a specialist adviser in sexual health, compared with referral to a genitourinary medicine clinic for partner notification by a specialist adviser in sexual health. ;

Study Design

Related Conditions & MeSH terms

Chlamydia Infections

Clinical Trial Details

NCT number	NCT00112255
Study type	Interventional
Source	University of Bristol
Contact
Status	Completed
Phase	Phase 3
Start date	March 2001
Completion date	December 2002

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00381992` - Risk Assessment of Long-Haul Truck Drivers	N/A
Completed	`NCT00115388` - Community-Based Trial of Screening for Chlamydia Trachomatis to Prevent Pelvic Inflammatory Disease	N/A
Completed	`NCT00005496` - Inflammation, Infection, and Future Cardiovascular Risk	N/A
Completed	`NCT00207506` - Lay Health Advisors for Sexually Transmitted Disease Prevention	Phase 1/Phase 2
Completed	`NCT00132457` - Use of Self-collected Vaginal Swabs as an Innovative Approach to Facilitate Testing for Repeat Chlamydia Infection	N/A
Completed	`NCT03073538` - Screening of Gonococcal and Chlamydial Infections in the Third Trimester
Terminated	`NCT00120770` - Cellulose Sulfate (CS) Gel and HIV in Nigeria	Phase 3
Completed	`NCT00001890` - Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections	Phase 2
Not yet recruiting	`NCT05727033` - Extraordinarily Fun Training Project in Compulsory Secondary Education - Sexually Transmitted Infections	N/A
Completed	`NCT00561028` - Chlamydia and Mycoplasma in Coronary Artery Disease	N/A
Completed	`NCT00252096` - Nucleic Acid Amplification Tests (NAATs) for the Diagnosis of Pharyngeal and Rectal Chlamydia and Gonorrhea Infections	N/A
Completed	`NCT00037388` - Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II	N/A
Terminated	`NCT01728103` - Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays	N/A
Completed	`NCT00607659` - Immunopathogenesis of Chlamydia	N/A
Completed	`NCT00000120` - Clinical Trial of Eye Prophylaxis in the Newborn	Phase 3
Completed	`NCT01638637` - Prospective Collection of Female and Male Specimens for PANTHER® System Testing	N/A
Completed	`NCT03374696` - Theater in School Sex Education - a Randomized Controlled Study	N/A
Active, not recruiting	`NCT00124878` - Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community	Phase 3
Completed	`NCT00005547` - Infection and Cardiovascular Disease	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.